Hyperfine (HYPR) Stock Forecast & Price Target

Hyperfine is well positioned for durable growth because its Swoop platform has moved beyond early adoption to more than 200 systems deployed worldwide, with rising hospital utilization, expanding office-channel demand, and the first steps of international rollout. The next-generation Model 2 hardware and recurring FDA-cleared Optive AI software updates improve image quality, scan speed, and clinical utility, while the company’s lean sales model, proven pricing power, and 12 Swoop systems sold in 2Q26 support revenue acceleration and operating leverage. Fundamentally, the investment case is reinforced by a compelling 1–1.5 year hospital ROI, a >$16B U.S. addressable market, gross margins above 50% for four consecutive quarters, and cash of $43.5M with runway into 2028.

Hyperfine is exposed to a fragile adoption curve for Swoop, and its relatively small, developing install base makes quarterly revenue and device placement inherently lumpy if customer uptake or install timing slows. The company also faces concentrated operational and financial risk from Benchmark Electronics and a single-source magnet supplier, while capital-intensive funding needs could force dilutive financing or even insolvency if market conditions tighten. Its negative outlook is further supported by intense competition from larger MRI players, plus international expansion and regulatory execution risks that could hinder market acceptance, approvals, and long-term growth.